The identification and characterisation of functional targets that play an essential role in tumour growth and survival, is of imperative importance to the success of novel cancer therapies. B-RAF, a member of the RAF kinase family, is an important new therapeutic target for a group of human cancers, as it constitutes activation of the RAF-MEK-ERK pathway common to numerous cancers [
1]. Recently, large-scale genomic screens have detected mutations in B-RAF in about 70% of malignant melanomas and at a lower frequency in colorectal and ovarian cancers [
2]. Other cancer types have been found to harbour B-RAF mutations. Over 40 mutations have already been identified [
3,
4]. Some of these mutants, B-RAF
E586K, B-RAF
V600E, B-RAF
V600D, B-RAF
V600K, B-RAF
V600R and B-RAF
K601E, have a much higher kinase activity
in vitro than the basal wild type B-RAF (B-RAF
WT) activity and were classified as strongly activating [
4]. Mutations at nine amino acid positions that are less activating, but exhibit activity above the basal, belong to an intermediate activity group [
4]. Although most B-RAF mutants display elevated kinase activity compared to the B-RAF
WT, four cancer-derived mutants have reduced kinase activity: B-RAF
G466E, B-RAF
G466V, B-RAF
G596R and B-RAF
D594V [
3,
4].
Most of the mutations of B-RAF are clustered in two different regions within the binding pocket, one is the glycine-rich P-loop (P-loop) of the N lobe and the other one is the activation segment (named A-loop here). A substitution of Val by Glu at residue 600 in the A-loop, adjacent to the conserved DFG motif, accounts for 90% of B-RAF mutations in human cancers. B-RAF
V600E has a 500-fold higher kinase activity, relative to the basal activity of B-RAF
WT, providing cancer cells with both proliferation and survival signals and allowing them to grow as tumours in model systems [
4].
The activation of B-RAF
WT requires phosphorylation of the Thr599 and/or Ser602 residues within the A-loop [
5]. It has been suggested that the V600 mutations mimic the phosphorylation step [
2], and has also been stated that most of the B-RAF mutants can activate MEK directly and thereby stimulate ERK [
3,
4]. However, the mutated and activated B-RAF
V600E binds to a Hsp90-cdc37 complex, which is required for its stability and function [
6]. Three of the impaired kinase activity mutations (B-RAF
G466E, B-RAF
G466V and B-RAF
G596R) are capable of inducing ERK phosphorylation through heterodimerization with C-RAF. The fourth mutant (B-RAF
D594V) acts like a kinase-dead mutant and cannot bind to C-RAF. Its role in tumorigenesis remains to be elucidated [
3]. It is not surprising that B-RAF
D594V is a loss-of-function mutant, because Asp594 is a key catalytic residue for many kinases [
7]. The impact of the D594V mutation on the B-RAF conformation, and in particular on the coordination and interaction with ATP binding residues such as Lys483, Glu501 and Asp594 is yet unclear.
Crystal structures of the inactive B-RAF
WT and B-RAF
V600E kinase binding domains in a complex with the BAY-439006 (Sorafenib) inhibitor have been solved [
4]. It has been suggested that the molecular interactions between the P-loop and the A-loop in B-RAF
WT stabilize the inactive form, and that the substrate recognition leads to conformational changes that set the catalytic cleft free and allows the enzyme to achieve a full active state [
4,
8]. In particular, interactions between Phe468 in the P-loop and Val600 in the A-loop were identified and based on this observation it has been predicted that the mutations of Val600 to a larger and more charged residues will lead to conformational change within the A-loop, flipping it to the active position. Such structural model could also explain the strong increase in the kinase activity caused by the G469A mutation in the P-loop and intermediate increase in activity for a group of other P-loop mutants. However, the molecular basis of the strong B-RAF activation by the K601E mutation remains unclear, and it is also difficult to explain the strong kinase activity by the B-RAF
E586K mutant, and the intermediate activation by the N581S, F595L, L597V, L597R and T599I mutations within in frame of the present literature model, because none of these residues are in a close contact with the P-loop. Moreover, the position of Phe468 in a newly obtained crystal structures of the inactive B-RAF
WT [
9] differs significantly from the corresponding position in previously solved crystal structures. The new data showed that in a presence of a ligand smaller than Sorafenib or with no inhibitor present in the binding site, Phe468 has an orientation toward the αC-helix and is unlikely to interact with Val600. The results from MD simulations of B-RAF
WT, B-RAF
V600E and B-RAF
V599Ins showed that the electrostatic interactions between the A-loop, the P-loop and the αC-helix are an important factor for the conformational stability of the activation segment in B-RAF
WT and in the mutations causing disruption of these interactions, but the particular contribution of the αC-helix to these processes was not specified [
10]. Further, the molecular bases for the ligand inhibition, selectivity and conformation stability in inactive B-RAF
WT and B-RAF
V600E has been studied, indicating that the αC-helix – A-loop interactions play a crucial role in B-RAF activation. In this study the Lys601 residue in the A-loop and the Glu501 residue in αC-helix were identified to provide the strongest electrostatic component to the overall interactions within the protein-ligand complex [
11].
Recently, crystal structures of the active form of B-RAF (B-RAF-A), i.e. the kinase with the A-loop moved to its active position, were obtained [
9,
12]. The conformational change of the A-loop is a major structural feature that occurs during the kinase activation [
3,
4,
12]. Due to its conformational flexibility, some of the residues in the A-loop were not resolved in all available crystal structures of the active as well as inactive B-RAF forms.
In the present paper we suggest a molecular basis for several of the experimentally observed B-RAF kinase activity deviations induced by the mutations. We study the direct and indirect changes caused by the mutants on a strong hydrogen bond network identified in the B-RAF wild type, and put forward a hypothesis on how the observed structural changes contribute to the experimentally measured kinase activity deviations.